DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) — The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), and Turbo Energy (NASDAQ:TURB).
Aethlon Medical: Radical Reset Puts NOR-101 in the Spotlight
Aethlon Medical (NASDAQ:AEMD) is attempting one of the most dramatic strategic resets in this group, announcing a definitive all-stock merger with privately held North Immunology alongside an oversubscribed private placement expected to generate approximately $180 million. If completed, the combined company is expected to operate as North Immunology and trade on Nasdaq under NASDAQ: NRTX. The transaction is targeted for the first quarter of 2027 and remains subject to shareholder, SEC, Nasdaq and other closing conditions.
The centerpiece is North Immunology’s NOR-101, a half-life-extended IL-13 × IL-18 bispecific antibody being developed for atopic dermatitis and potentially other immune-mediated diseases. North says the financing should fund operations into the second half of 2028, while its current development plan calls for a Phase 1a study in the first quarter of 2027, interim pharmacokinetic and safety data by mid-2027, and Phase 1b and Phase 2b topline data in 2028.
“By simultaneously targeting type 2 and non-type 2 inflammatory pathways that drive AD, we believe NOR-101 has the potential to deliver a best-in-disease therapeutic profile,” North Immunology Co-Founder and CSO Mohit Gupta said. The company has also reported an approximately 42-day half-life for NOR-101 in a non-human-primate pharmacokinetic study. Those are preclinical findings, however, and NOR-101 has not yet generated human clinical efficacy or safety data.
The transaction dramatically changes the economics for existing Aethlon shareholders. At closing, pre-merger Aethlon shareholders are expected to own approximately 4.75% of the combined company, while pre-merger North shareholders and participating financing investors are expected to own approximately 95.25%. Aethlon shareholders would also receive contingent value rights tied to potential future monetization of the legacy Hemopurifier business. The result is a company story that is moving decisively away from the legacy device platform and toward NOR-101 and clinical-stage immunology.
NeOnc Technologies Holdings: Capital Structure Gets a Major Cleanup
NeOnc (NASDAQ:NTHI) is attacking a different kind of overhang: potential equity dilution. The company announced that it redeemed all 6,000 outstanding Series A Convertible Preferred shares for $6 million in cash, leaving no Series A Preferred shares outstanding and issuing no common stock in the redemption. The cash came from the net proceeds of NeOnc’s recently announced $15 million registered direct offering.
The timing is significant because the preferred shares contained a discounted conversion mechanism. NeOnc issued the Series A Preferred Stock in June 2026 for $5 million in gross proceeds. Under its terms, if the company had not redeemed the securities within the specified period, the stated value would have increased by $166.67 per share and holders could have elected to convert into common stock at 80% of the lowest closing price during the five trading days before conversion, subject to a $1 floor.
“We made a deliberate decision to redeem the Series A Preferred Stock in cash and eliminate the potential dilution these securities represented for our shareholders,” CEO Amir F. Heshmatpour said. He added that the financing enabled the company to retire the preferred stock before its discounted conversion feature became available.
The capital-structure move comes as NeOnc advances its CNS oncology programs NEO100 and NEO212. The company’s September 9 financing involved 3,571,430 shares of common stock or pre-funded warrants, plus warrants, at a combined purchase price of $4.20 per share or pre-funded warrant.
bioAffinity Technologies: Patent Protection Adds Another Layer to the CyPath Lung Story
bioAffinity (NASDAQ:BIAF) is building a different type of catalyst: intellectual-property expansion around its CyPath Lung diagnostic. The company reported patent protection for its technology in Hong Kong, complementing a China patent granted in 2025 and broader patent coverage and pending applications across multiple international markets. The technology uses defined antibodies, the fluorescent porphyrin TCPP and flow cytometry to characterize cell populations in sputum.
The underlying commercial asset is CyPath Lung, a noninvasive sputum-based Laboratory Developed Test designed to help physicians assess the likelihood of malignancy in patients with lung nodules detected through imaging. The test combines flow cytometry with artificial intelligence and a fluorescent porphyrin that is preferentially taken up by cancer and cancer-associated cells.
The company continues to point to published clinical data showing 92% sensitivity, 87% specificity and 88% accuracy in high-risk patients with small indeterminate lung nodules below 20 millimeters. A peer-reviewed publication in Respiratory Research reported the 92% sensitivity and 87% specificity for that subgroup.
More recent company case studies have highlighted potential use in clinical decision-making around suspicious nodules, including situations where physicians may choose surveillance rather than immediately pursuing invasive procedures.
The important qualifier is that CyPath Lung is not intended to be used as a standalone diagnostic and the published performance figures relate to the detection setting. The new Asian patent protection therefore strengthens the company’s intellectual-property position, but the larger commercial question remains whether bioAffinity can translate that technology and clinical evidence into broader adoption and market penetration.
Turbo Energy: 15 Storage Projects Turn the AI Energy Pitch into Physical Infrastructure
Turbo Energy (NASDAQ:TURB) is showing tangible commercial activity in the rapidly expanding energy-storage market, announcing 15 firm-order commercial and industrial projects across Spain and Chile with an estimated aggregate order value attributable to the company of approximately €3 million, or $3.48 million. The portfolio represents 15.6 MWh of storage capacity and 5.95 MW of power.
The projects cover a broad range of applications, including solar time-shifting, self-consumption optimization, peak-demand management, off-grid power, EV charging and grid-interruption mitigation. The execution mix is notable: two systems are already operating, three are under installation, nine are in manufacturing and one is under development. Turbo Energy expects the projects not yet operating to progress through delivery and commissioning between Q4 2026 and H1 2027, subject to customer readiness and other conditions.
The new portfolio is separate from the company’s previously announced 366 MWh Pamesa Net Zero deployment under a $53 million contract, giving investors two different examples of Turbo Energy’s commercial model: a large industrial deployment and a diversified collection of smaller C&I installations. CEO Mariano Soria said customers are looking beyond battery capacity toward “an intelligent energy layer capable of coordinating generation, storage and demand around the economics of their operations.”
There is, however, a crucial financial distinction. The €3 million represents the estimated aggregate order value attributable to Turbo Energy and does not represent revenue recognized in a single reporting period. Revenue and cash collection depend on contractual milestones and actual execution. Still, the combination of signed orders, systems already operating and projects moving through manufacturing gives NASDAQ: TURB a concrete deployment pipeline to watch through 2027.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Media gallery
